EVMN ▲ +5.7% - Evommune, Inc.
$EVMN - Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
01-OCT-2026 08:09 AM ET
Share this post
More filings for $EVMN
EVMN ▼ -8.6% - Evommune, Inc.Sep 23, 2026EVMN ▼ -8.6% - Evommune, Inc.Sep 23, 2026EVMN ▼ -13.6% - Evommune, Inc.Sep 8, 2026EVMN ▼ -25.2% - Evommune, Inc.Sep 8, 2026$EVMN SEC Filing Update (16-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 16, 2026
View full $EVMN filing history →💬 Comments
Loading comments…
Leave a comment